FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to novel compounds of the formula (I): 
wherein R means -C(O)R1 wherein R1 is chosen from the series: (C1-C6)-alkyl, -C=CH-COOH, -NHCH2-CH2R2, -N(CH2-CH2OH)CH2-CH2OH, -N(CH3)CH2-CH2-NHCH3, -N(CH3)CH2-CH2N(CH3)CH3, saturated 4-, 5- and 6-membered cycles and saturated and unsaturated 5- and 5-membered cycles comprising at least one heteroatom from a series sulfur (S), nitrogen (N) and oxygen (O), and optionally substituted with a group chosen from the series: (C1-C6)-alkyl, -C=O-R5, -OH, (C1-C6)-alkyl substituted with hydroxy-group optionally, (C1-C6)-alkyl substituted optionally with a group of the series: -NH2, -N-(C1-C6)-alkyl, -SO2CH3, =O, and 5- and 6-membered saturated cycles comprising at least one heteroatom chosen from N and O, and wherein R5 is chosen from the series: hydrogen atom (H), (C1-C6)-alkyl, (C1-C6)-alkyl substituted with hydroxy-group optionally, and (C1-C6)-alkyl substituted with NH2-group optionally; R2 is chosen from the series: -N(CH3)CH3, -NH2, morpholinyl and piperazinyl; X1, X2 and X3 are chosen independently from the series: -OH, (C1-C2)-alkyl, (C1-C6)-alkoxy-group, -Cl, -Br, -F, -CH2OCH3 and -CH2OCH2CH3, or one among X1, X2 or X3 means hydrogen atom, and two others are chosen independently from the series: hydroxy-group, (C1-C6)-alkyl, (C1-C6)-alkoxy-group, -Cl, -Br, -F, -CF3, -CH2OCH3, -CH2OCH2CH3, -OCH2-CH2R3, -OCH2-CF3 and -OR4, morpholylmethyl, -N(CH3)CH3, -CH2OH, -COOH, or one among X1, X2 or X3 means hydrogen atom, and two others in common with two carbon atoms including bonds between them in benzene cycle to which they are bound optionally form 5- or 6-membered saturated cycle comprising at least one heteroatom chosen from S, N and O, and wherein R3 is chosen from the series: -F, -OCH3, -N(CH3)CH3, saturated 5-membered cycle comprising at least one heteroatom N; R4 means 3-5-membered saturated cycle, and each Y1 and Y2 is chosen independently from the series: -Cl, -Br, -NO2,-C≡N and C≡N, and compound of the formula (II) also given in the invention description. Also, invention relates to a pharmaceutical composition possessing anti-proliferative activity and based on these compounds. Invention provides preparing novel compounds possessing the useful biological properties.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
28 cl, 39 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CIS-IMIDAZOLINES AS MDM2 INHIBITORS | 2004 |
|
RU2354649C2 |
| DERIVANTS OF 2, 4, 5-TRIPHENYLIMIDAZOLINE AS INACTIVATORS OF INTERACTION BETWEEN P53 AND MDM2 PROTEINS DESIGNED FOR APPLICATION AS ANTICANCER DRUGS | 2006 |
|
RU2442779C2 |
| NEW CIS-IMIDAZOLINES | 2005 |
|
RU2408593C2 |
| CHIRAL CIS-IMIDAZOLINES | 2008 |
|
RU2487127C2 |
| CIS-2,4,5-TRIARYLIMIDAZOLINES AND USE THEREOF AS ANTICANCER MEDICINAL AGENTS | 2006 |
|
RU2411238C2 |
| 2-ARYL-SUBSTITUTED N-ARYLIMIDAZOLINES, SELECTIVE CYCLOOXYGENASE-2 INHIBITORS, METHODS FOR PRODUCTION AND USE THEREOF | 2014 |
|
RU2565667C1 |
| CIS-IMIDAZOLINES AS INHIBITORS OF MDM2 | 2002 |
|
RU2312101C2 |
| BENZIMIDAZOLE AND IMIDAZO[4,5-c]PYRIDINE DERIVATIVES AS HEDGEHOG PATHWAY ANTAGONIST | 2010 |
|
RU2533825C2 |
| 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | 2000 |
|
RU2270193C2 |
| GLUTAMINE FRUCTOSE-6-PHOSPHATE AMIDOTRANSFERASE INHIBITORS | 2004 |
|
RU2355686C2 |
